Poolbeg Pharma Secures First National Patent for Cancer Immunotherapy Programme

Poolbeg Pharma PLC has announced the grant of its first national patent covering the POLB-001 programme, which addresses cytokine release syndrome induced by cancer immunotherapy. The development represents a significant milestone in the company’s strategic expansion into oncology and arrives ahead of anticipated interim clinical data later this year.

Chief executive Jeremy Skillington confirmed that IP Australia had granted the patent following a comprehensive examination process. The protection covers the use of P38 MAPK inhibitors, including POLB-001, for the prevention of cytokine release syndrome associated with cancer immunotherapy treatments. The scope of the patent is underpinned by proprietary data generated by Poolbeg and reflects the robustness of the company’s scientific approach.

Skillington characterised the patent grant as a pivotal achievement for the business, noting that it establishes the company’s first formal intellectual property position within the cancer immunotherapy sector. The timing, he suggested, is particularly advantageous given the expected release of interim clinical data during the summer months. This confluence of events positions Poolbeg to engage more substantively with potential pharmaceutical partners.

The company originally filed oncology patent applications in the United Kingdom in January 2023, subsequently following with a Patent Cooperation Treaty application in January 2024 to expedite examination processes across multiple jurisdictions. Poolbeg already holds patent protection for its work in influenza and hypercytokinaemia, and the extension into oncology demonstrates strategic progression across its portfolio.

Skillington emphasised the critical importance of intellectual property protection when engaging with major pharmaceutical companies. He explained that drug development programmes typically require investments running into billions of pounds, making patent protection essential for securing periods of market exclusivity. This exclusivity provides the commercial framework necessary to justify such substantial capital outlays and reduces the risk profile associated with generic competition.

The chief executive outlined that whilst pharmaceutical partners evaluate multiple factors when considering collaboration opportunities, intellectual property remains a fundamental consideration. Strong patent coverage reduces uncertainty and enhances the long-term commercial viability of development programmes, making them more attractive to potential partners.

Looking forward, Poolbeg intends to expand its intellectual property portfolio by pursuing protection for P38 MAPK inhibitors in treating cancer immunotherapy-induced cytokine release syndrome across additional territories. The company plans to utilise accelerated examination pathways, including the patent prosecution highway, to facilitate this expansion. Concurrently, the clinical team remains focused on executing the ongoing trial programme with the objective of delivering interim data during the summer period.

The Australian patent grant provides Poolbeg with a strengthened position as it advances towards potential partnership discussions. With interim clinical data on the horizon and expanding intellectual property protection, the company appears well positioned to progress its oncology programme and demonstrate value to both investors and potential pharmaceutical collaborators.